Phase IV studies - Dr. Oestreich + Partner GmbH

After the successful completion of phases I to III, phase IV studies investigate an approved drug in the widespread treatment of patients. The particular benefit of the Phase IV studies is the comprehensive documentation of the tolerability of the medication with a higher number of cases subject to meticulous documentation of side effects and interactions with other medication. The incurring data volumes in phase IV studies are consequently large and require complex editing systems that facilitate intelligent error correction and error prevention.

Click here for more information about Phase IV studies at Dr. Oestreich + Partner:

Phase IV studies

Flexible data transmission for Phase IV studies

With our OPVERDI and PMSBOX software, we offer our clients’ customizable rapid data capture and data transmission for all project participants. Both documentation systems are accessible to authorized staff via the Internet. Thus, investigators and all project members involved can access all relevant data of the Phase IV studies anywhere at any time. The team at Dr. Oestreich + Partner is always available to all project staff to answer any questions or solve any problems which may arise without delay. The software can be flexibly adapted to the phase IV studies and also incorporates external data such as images from diagnostic procedures, laboratory results or ECGs. The documentation systems facilitate the electronic generation of all required documentation forms (eCRFs) in all languages for phase IV studies.  At the same time, Dr. Oestreich + Partner offers a reliable compliance monitoring system for clinical research. Our team of experts from a wide range of medical fields provides competent advice on compliance with all regulatory requirements and good clinical practice (GCP).

Click here for more information on Phase IV studies:

Phase IV studies


EMEA Pharmacovigilance
Health care studies
Observational studies
EMA Pharmacovigilance
Medical Biometrics
Approval of Medical Devices
Pharmacovigilance
Clinical Investigators
Clinical Trials
GCP Legislation
GCP - Good Clinical Practice
ICH GCP E6
GCP Guidelines
GCP Compliance
BfArM GCP
CRO – Clinical Research Organisation
CRO – Contract Research Organisation
PSUR
PSURs
Pharmacoeconomics, Health
Pharmacoeconomic studies
Pharmacoeconomics
Patient Monitoring
Monitoring Clinical Trials
Clinical Monitor
Marketing Authorisation
Medicinal Product Approval
Drug safety
Data management plan
Clinical development
Monitoring investigators
Non-interventional studies (NIS)
Patient recruitment
Phase IV studies
Investigator audit
Investigator qualification
Investigator selection

EMEA Pharmacovigilance · Health care studies · Observational studies · EMA Pharmacovigilance · Medical Biometrics · Approval of Medical Devices · Pharmacovigilance · Clinical Investigators · Clinical Trials · GCP Legislation · GCP - Good Clinical Practice · ICH GCP E6 · GCP Guidelines · GCP Compliance · BfArM GCP · CRO – Clinical Research Organisation · CRO – Contract Research Organisation · PSUR · PSURs · Pharmacoeconomics, Health · Pharmacoeconomic studies · Pharmacoeconomics · Patient Monitoring · Monitoring Clinical Trials · Clinical Monitor · Marketing Authorisation · Medicinal Product Approval · Drug safety · Data management plan · Clinical development · Monitoring investigators · Non-interventional studies (NIS) · Patient recruitment · Phase IV studies · Investigator audit · Investigator qualification · Investigator selection